atepeq/tico19 huggingface dataset:
On 18 March, the WHO announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the Solidarity clinical trial.
a ranar 18 ga watan maris WHO ta sanar cewa choloroquine da dangin hydroxychloroqueen na daga ciki magunguna hudu wanda za a yi gwajin kiwon lafiya dasu na hadin kai.
New York governor Andrew Cuomo announced that New York State trials of chloroquine and hydroxychloroquine would begin on 24 March.On 28 March, the FDA authorized the use of hydroxychloroquine sulfate and chloroquine phosphate under an Emergency Use Authorization (EUA).
Gwamnan New York Andrew Cuomo ya ba da sanarwar cewa gwaji na jihar New York zai fara aiki a ranar 24 ga Maris. A ranar 28 ga Maris, FDA ta ba da izinin yin amfani da hydroxychloroquine sulfate da chloroquine phosphate a karkashin Izinin Amfani na gaggawa (EUA).
The treatment has not been approved by the FDA's clinical trials process and is authorized under the EUA only as an experimental treatment for emergency use in patients who are hospitalized but are not able to receive treatment in a clinical trial.
Ba a yardada tsarin jinyar gwajin asibiti wanda FDA'S su ka yi ba kuma an ba shi izini a karkashin EUA kawai azaman jinyar gwaji don amfani na gaggawa a cikin marasa lafiya da ke asibiti amma ba su iya karɓar magani a cikin gwajin asibiti ba
The CDC has said that "the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" are not yet established.
CDC ta ce "ba a kafa amfani da, allura, ko tsawon lokacin hydroxychloroquine don maganin cizon prophylaxis ko kula da kamuwa da cututtukan SARS-CoV-2" ba tukuna.
Doctors have said they are using the drug when "there's no other option".
Likitoci Sun ce Suna Amfani Da Kwayar maganin In “Babu Mafita”.
A Turkish research team in Istanbul is conducting a small study on the use of chloroquine in combination with zinc, vitamin A, vitamin C and vitamin D.
Wata tawaga da ke bincike a Turkiyya a Istanbul na gudanar da karamin bincike kan amfanin chloroquine a hade da zinc, Vitamin A, Vitamin C da Vitamin D.
Large studies are underway at Duke University and the University of Oxford.
bincike babba na guddana a jami’ar duke da ma jami’ar oxford .
NYU Langone Medical School is conducting a trial on the safety and efficacy of preventative use of hydroxychloroquine.
nyu makarantar karatun likita na gwajin wani matakin kariya da ma rsahin amfani da hydroxychloroquine.
Chinese clinical trials in Wuhan and Shenzhen claimed to show favipiravir was "clearly effective".
Gwajin asibiti na kasar Sin a Wuhan da Shenzhen sun ce sun nuna favipiravir "a bayyanen inganci".
35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
Marasa lafiya 35 a Shenzhen gwajin ta nuna ba su da cutar ba a tsakiyar kwana 4, yayin da tsawon rashin lafiya ya kasance kwanaki 11 a cikin marasa lafiyar 45 waɗanda ba su kamu da shi ba.
In a study conducted in Wuhan on 240 patients with pneumonia, half were given favipiravir and half received umifenovir.
A cikin wani binciken da aka yi a Wuhan a kan mutane 240 da ke fama da cutar huhu, rabi ne aka ba su fulopiravir kuma rabi suka karɓi umifenovir.
The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.
hukuma magani na italia na tiunasar wa akan tabacin tallafi na magani da gwajin shi.
On 2 April, Germany announced that it would purchase the drug from Japan for its stockpile, and use the military to deliver the drug to university hospitals, where the drug will be used to treat COVID-19 patients.
A ranar 2 ga watan Afrilu, Jamus ta sanar cewa za ta sayi maganin daga Japan don ajiyar ta, kuma za ta yi amfani da sojoji wajen isar da maganin a asibitocin jami'a, inda za a yi amfani da maganin don yi wa marasa lafiya na COVID-19.
According to the South China Morning Post, Shinzo Abe has made overtures to the Trump administration about purchasing the drug.The drug may be less effective in severe cases of illness where the virus has already multiplied.
Bisa ga rahoton Morning Post na China ta Kudu, Shinzo Abe ya yi yarjejeniya ga gwamnatin Trump domin sayawar magani. Maganin na iya zama mara karfi cikin cututtuka masu tsanani inda kwayar cutan ta yadu.
It may not be safe for use by pregnant women or those trying to conceive.
Yana iya zama ba amintaccen amfani ga mata masu juna biyu ko waɗanda ke ƙoƙarin yin ciki.
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".
Daya daga cikin binciken lopinavir / ritonavir (Kaletra), haɗuwa da maganin rigakafin lopinavir da ritonavir, sun kammala cewa "babu wani fa'ida da aka gani".
The drugs were designed to inhibit HIV from replicating by binding to the protease.
an shiyar maganin ne ta yanda zai hana HIV zama a ciki da ma kamanceceniya da hadewar protese.
A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS.
Wata ƙungiyar masu bincike a Jami'ar Colorado suna ƙoƙarin sauya magungunan don samo wani fili wanda zai ɗaure tare da kariya ta SARS-CoV-2.Da akwai zargi a cikin ƙungiyar kimiyya game da ba da gudummawar albarkatun don sake dawo da magunguna musamman da aka tsara don cutar HIV / Kanjamau.
The WHO included lopinavir/ritonavir in the international Solidarity trial.
Hukumar ta WHO ta hada da lopinavir / ritonavir a cikin shari'ar Solidarity ta kasa da kasa.
Remdesivir was created and developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections . Gilead Sciences subsequently discovered that Remdesivir had antiviral activity in vitro against multiple filo-, pneumo-, paramyxo-, and corona- viruses .
Remdesivir ya kirkiro da haɓaka ta Gilead Sciences a matsayin kwayar cutar Ebola da kamuwa da cutar Marburg. Bayan haka, ilimin kimiyyar Gileyad ya gano cewa Remdesivir yana da aikin rigakafi a cikin fitsari a kan ƙwayoyin cuta masu yawa, ƙwayoyin cuta, paramyxo-, da ƙwayoyin cuta.
One issue with antiviral treatment is the development of resistance through mutations that can lead to more severe disease and transmission.
Daya daga cikin matsalolin warkar da irin wannan cuta shi ne yakan bijirewa magani ta hanyar sake launi wanda ka iya haifar da wasu cututuka masu tsanani da yaduwa.
Some early pretrial studies suggest remdesivir may have a high genetic barrier to resistance.There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.
Wasu daga farkon bincike da aka yi sun nuna cewa karatun zai iya samun babbar illa ta hanyar juriya. Akwai gwaji na asibiti da yawa, wadanda suka hada da asibitocin Jami'ar Cleveland guda biyu; daya na mutanen da ke da matsakaici na rashin lafiya da kuma wani don waɗanda ke da tsananin ciwo.
There are three ongoing clinical trials of intravenous vitamin C for people who are hospitalized and severely ill with COVID-19; two placebo controlled (China, Canada) and one with no control (Italy).
Akwai gwajin asibiti guda uku masu wanda ake gudanarwa na bitamin C ta cikin Jijiyar jini don mutanen da ke asibiti da rashin lafiya mai tsanani domin COVID-19; sarrafawar maganin gwaji guda biyu (Sin, Kanada) da daya wanda babu sarrafawa (Italiya)
New York State began trials for the antibiotic azithromycin on 24 March 2020.
Jihar New York ta fara gwajin garkuwan halita azithromycin a ranar 24 ga watan Maris 2020.
Japan's National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin's Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus.
hukumar kasar japan ta lafiya da magani a duniya NCGM na shirin gwaji teijin alvesco ciclisionide abun shaka na corticosteriod na asthma domin warkar da kamun farko na cutar corona.
A form of angiotensin-converting enzyme 2, a Phase II trial is underway with 200 patients to be recruited from severe, hospitalized cases in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
Wani nau'i na angiotensin-mai canza yanayin enzyme 2, an fara gwaji yeneyi Phase II tare da marasa lafiya 200 don ɗaukar su daga mummunan, cututtukan asibiti a Denmark, Jamus, da Austria don sanin tasirin magani.
Researchers from the Montreal Heart Institute in Canada are currently studying the role of colchicine in reducing inflammation and pulmonary complications in patients suffering from mild symptoms of COVID-19.
Masu Bincike A Makarantar Zuciya Ta Montreal Na Kasar Canada Na bincikan matsayin Colchicine a ragewar kumburi da rikitarwa huhu a marasa lafiya wanda suke Fama Daga Karamin alamun ciwon COVID-19.
The study, named COLCORONA, is recruiting 6000 adults aged 40 and over who were diagnosed with COVID-19 and experience mild symptoms not requiring hospitalization.
binciken mai suna colcorona na dauka sama da mutane 6000 masu shekara 40 sama wanda suka kamu da covid-19 kuma sun dana makarancin hali ba na asibiti ba.
Women who are pregnant or breastfeeding or who do not have an effective contraceptive method are not eligible.
Matan da ke da juna biyu ko masun bada nono ko kuma ba su da ingantaccen tsarin hana haihuwa, ba su cancanta ba.
Several anticoagulants are being tested in Italy.
da dama anticoagulants ana ta gwada su a ksar italy.
Low-molecular-weight heparin is being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.
ana amfani da low molecular weight wajen warkar da majinyata, wanda hakan yasa hukumomin italia suka wallafa kaidojin amfani da shi.
A multicenter study on 300 patients researching the use of enoxaparin sodium at prophylaxis and therapeutic dosages was announced in Italy on April 14.
wani bincikie ya nuna majinyata 300 na amfani da enoxaparin sodium da prophylaxix da therapautickimar da aka sanar a 14 a afrilu.
Since SARS-CoV-2 is a virus, considerable scientific attention has been focused on repurposing approved anti-viral drugs that were developed for prior outbreaks such as MERS, SARS, and West Nile virus.
Tunda SARS-CoV-2 kwayar cuta ce, an mayar da hankali sosai kan batun kimiyya don mayar da martani don ƙaddamar da magungunan rigakafin da aka yarda da su wanda aka kirkira don barkewar cutar kamar MERS, SARS, da kwayar cutar ta West Nile.
Ribavirin: ribavirin was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Ribavirin: An bada shawarar jinyar COVID-19 da Ribavirin bisa ga bugun ka'idoji na 7 kasar Sin
Umifenovir: umifenovir was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Umifenovir: an ba da shawarar umifenovir don maganin COVID-19 bisa ga ka'idoji na 7 na kasar Chinese
Some antibiotics that have been identified as potentially repurposable as COVID-19 treatments:
wasu magungun na iya warkar da covid-19.
Tocilizumab (Anti-IL-6 receptor): Approved by China.
Tocilizumab (Anti-IL-6 receptor): China ta amince da shi.
Also trials in Italy and China. and see Tocilizumab#COVID-19.
kuma gwaji a italy da china ku kalli Tocilizumab #COVID-19.
It is unclear yet whether conditions arising during pregnancy including diabetes, cardiac failure, hypercoagulability or hypertension might represent additional risk factors for pregnant people as they do for nonpregnant people.From the limited data available, vertical transmission during the third trimester probably does not occur, or only occurs very rarely.
Ba a sani ba tukuna ko yanayin da ya taso yayin daukar ciki har da ciwon sukari, bugun zuciya, hauhawar jini ko hauhawar jini na iya wakiltar ƙarin abubuwan haɗari ga masu juna biyu kamar yadda suke yi ga mutanen da ba su da haihuwa. ko kawai yakan faru da wuya.
There is no data yet on early pregnancy.
Babu wani bayani tukuna game da lokacin daukar ciki.
Little evidence exists to permit any solid conclusions about the nature of COVID-19 infection in pregnancy.
Karancin shaida ya wanzu don ba da izini ga kowane ƙarshen yanke shawara game da yanayin COVID-19 a cikin mata masu juna biyu.
A case series of 43 women from New York who tested positive for COVID-19 showed similar patterns to non-pregnant adults: 86% had mild disease, 9.3% had severe disease and 4.7% developed critical disease.
An Samu jerin Mata Majinyata mata 43 Daga New York wadanda gwaji ya nuna sun kamu da CoVID-19 ya nuna alamu iri daya ga manya mata marasa ciki: kashi 86% suna da karamin ciwo, kashi 9.3% suna ciwo mai tsanani da kashi 4.7% sun bullo da mumunar cuta.
Fetal distress was reported in two.
An ruwaito gajiyar jaririn cikin mahaifa a cikin biyu.
None of the women developed severe COVID-19 pneumonia or died.
ba bu cikin matan wan da suka kamu da covid-19 ko sani ko mutuwa.,
All of them had live birth pregnancies and no severe neonatal asphyxia was observed.
dukkan su un yo fama da juna biyu ba tare da tsananin neonatal asphyxia aka gano.
The samples of breast milk, amniotic fluid, cord blood and neonatal throat swab were tested for SARS-CoV-2, and all results were negative.In another study on 15 pregnant women, majority of the patients presented with fever and cough, while laboratory tests yielded lymphocytopenia in 12 patients.
An gwada samfuran madarar nono, ƙwayar amniotic, igiyar jinin ciki da swab ne na makogwaro don SARS-CoV-2, kuma duk sakamakon ya kasance mara kyau. A cikin wani binciken kan mata masu juna biyu 15, yawancin marasa lafiyar da aka gabatar tare da zazzabi da tari, yayin da dakin gwaje-gwaje sun samar da ƙwayar cutar ta lymphocytopenia a cikin marasa lafiya 12
Computed tomography findings of these patients were consistent with previous reports of non-pregnant patients, consisting of ground-glass opacities at early stage.
Bayanan da aka tattara na majinyatan na da alaka ta rahoton baya na marsa juna biyu hakan na cikin kwabalr kasa na zangon farko.
Follow-up images after delivery showed no progression of pneumonia.Media reports indicate that over 100 women with COVID-19 might have delivered, and in March 2020, no maternal deaths were reported.
Hotunan da aka biyo bayan bayarwa bai nuna wani ci gaba na ciwon huhu ba. Rahotanni sun nuna cewa sama da mata 100 masu dauke da COVID-19 sun iya haihuwa, kuma a cikin Maris 2020, ba a sami rahoton mutuwar mata masu juna biyu ba.
Their guidelines thus advise that any pregnant person admitted to hospital with a COVID-19 infection should receive at least 10 days of prophylactic low-molecular-weight heparin after being discharged from the hospital.
Ka'idodin su suna ba da shawara cewa duk wata mai ciki da aka shigar da ita asibiti a dalilin kamuwa da COVID-19 ya kamata ta sami aƙalla kwanaki 10 na prophylactic low-molecular-weight heparin bayan an sallame ta daga asibiti.
There are no data yet concerning the implications of COVID-19 infections for labour.
Babu bayanai tukuna game da abubuwan da ke tattare da cututtukan COVID-19 don aiki.
One infant girl born to a mother with COVID-19 had elevated IgM levels two hours after birth, suggesting that she had been infected in utero and supporting the possibility of vertical transmission in some cases.
Wata jinjiran yarinya wanda mahaifiyar na da cutar COVID-19 ta nuna mataki biyu na IgM sa'o'i biyu bayan haifuwa, ya nuna cewa ta kamu da cutar cikin mahaifa wanda yake goyon bayan yiwuwar yadawar daga maman zuwa yaro a cikin mahaifa.
A small study involving 6 confirmed COVID-19 mothers showed no indication of SARS-COV-19 in their newborns' throats or serum but antibodies were present in neonatal blood sera samples, including IgM in two of the infants.
Karamin binciken da ya haɗa da uwaye 6 na COVID-19 bai nuna alamar SARS-COV-19 a cikin kumburin jarirai ko ƙwayoyin jini ba amma ƙwayoyin rigakafi suna nan a cikin samfuran jinin, gami da IgM a cikin biyu na jarirai.
This is not usually passed from mother to fetus so further research is required to know whether the virus crossed the placenta or whether placentas of women in the study were damaged or abnormal.
Wannan ba yawanci ba ne daga mahaifiya zuwa tayin don haka ana buƙatar ƙarin bincike don sanin ko kwayar cutar ta ƙetare cikin mahaifa ko kuma ƙwayoyin mata da ke cikin binciken sun lalace ko ba mahaukaci ba.
Since COVID-19 shows similarities to SARS-CoV and MERS-CoV, it is likely that their effect on pregnancy are similar.
tunda covid-19 ta nuna kamani da Sars-cov da mers cov da kyar in ba illlar su akan juna biyu iri day bane.
Four of seven had first trimester miscarriage, two of five had fetal growth restriction in the second trimester, and four of five had preterm birth.
Hudu cikin bakwai na da bari a farkon wata uku, biyu cikin biyar na da ƙuntatawar girman jaririya wanda ba a haifa ba tukuna watani uku na biyu, da hudu cikin biyar na haihuwa kafin lokaci.
None of the newborns were infected with SARS-CoV.
Duk sabuar haiuwar ba wanda aka samu dauke da cutar SARS Cov.
A report of ten cases of MERS- CoV infection in pregnancy in Saudi Arabia showed that the clinical presentation is variable, from mild to severe infection.
wani rahoto mutum goma masu dauke da cutar MERS- CoV a masu ciki a saudi arabia, ya nuna bayanan kiwon lafiya na da nasaba dangane da karanci to tsananin cutar.
The outcome was favorable in a majority of the cases, but the infant death rate was 27%.A recent review suggested that COVID-19 appeared to be less lethal to mothers and infants than SARS and MERS but that there may be an increased risk of preterm birth after 28 weeks' gestation.
Sakamakon ta dace a cikin mafi yawan masu kamu da cutar, amma yawan mutuwan jariri kashi 27%. Binciken kwana nan ya nuna cewa mutuwar su mama da jarirai daga COVID-19 ya yi kasa in an kwatanta shi da SARS da MERS amma ana iya samun haɗarin haɓakar haihuwar bayan girma a ciki na makoni 28.
The World Health Organization and Centers for Disease Control and Prevention of the United States advises pregnant women to do the same things as the general public to avoid infection, such as covering cough, avoid interacting with sick people, cleaning hands with soap and water or sanitizer.
Hukumar Lafiya Ta Duniya da Cibiyar Kariya da Lurawar Cuta Na U.S. sun Shawarci Masu Juna Biyu Da Su Bi matakan kare kai Kamar yadda kowa ke bi domin a guje kamuwa da cuta, kamar rufe tari, guje hulda da marasa lafiya, wanke hannuwa da sabulu da ruwa ko mai tsaftacewa.
A survey conducted in Shanghai among pregnant women in different trimesters of pregnancy identified a strong demand for online access to health information and services.
Binciken da aka gudanar a Shanghai tsakanin mata masu juna biyu a cikin lokuta daban-daban na ciki ya gano babbar bukatar samun damar yanar gizo ga bayanan kiwon lafiya da aiyuka.
People expecting their first baby were more willing to have online consultation and guidance than who had previously given birth.The RCOG and RCM recommend that in-person appointments be deferred by 7 days after the start of symptoms of COVID-19 or 14 days if another person in the household has symptoms.
Mutanen da ke tsammanin ɗan farinsu na fari sun fi son yin shawarwari ta hanyar kan layi ta hanyar waɗanda suka taɓa ba da haihuwa. RCOG da RCM suna ba da shawarar cewa a ba da izinin ganawa da mutum cikin kwanaki 7 bayan fara alamun COVID-19 ko 14 idan wata mutum a gidan yana da alamu.
Fever subsequently developed in three asymptomatic patients.
Zazzabi Ya bullo kwana nan daga Wasu marasa lafiya wanda ke nuna kamuwa da cutar su Uku.
One patient who had tested negative subsequently became symptomatic postpartum and tested positive three days after the initial negative test.
Marasa lafiya guda wanda bayan gwaji ba a sami wata cuta ba daga baya ya zama alamar cutar kuma aka sake gawjin bayan kwana uku an samu cutar.
The doctors conducting the screening recommended that in order to reduce infection and allocate PPE, due to high numbers of patients presenting as asymptomatic, universal screening of pregnant patients should be conducted.
Likitocin da ke gudanar da aikin tantancewar sun ba da shawarar cewa, don rage kamuwa da cuta da kuma sanya PPE, saboda yawan lambobin marasa lafiya da ke gabatar da matsayin asymptomatic, ya kamata a gudanar da gwaje-gwaje na duniya game da masu juna biyu.
They also suggest that people with suspected or confirmed COVID-19 should have continuous electronic fetal monitoring.
Sun kuma bayar da shawarar cewa mutanen da ake zargi ko aka tabbatar da COVID-19 ya kamata su ci gaba da sa ido kan aikin tayi na lantarki.
The use of birthing pools is not recommended for suspected or confirmed cases of COVID-19 due to the risk of infection via faeces.
Ba'a ba da shawarar amfani da ruwan haihuwa ba don zaton ko tabbatar da yiwuwar cutar COVID-19 saboda haɗarin kamuwa da cuta ta hanyar kashi.
In the UK, official recommendations state that precautionary separation of a mother and a healthy baby should not be undertaken lightly and that they should be kept together in the postpartum period where neonatal care is not required.Literature from China recommended separation of infected mothers from babies for 14 days.
A kasar Ingila shawarwari na hukumomi na cewa rabe-rabe na kare kai tsakanin uwa da ya ba za a dauke shi sakwa-sakwa ba kuma a ajiye su a tare a tsawon lokacin da idan babu bukatar kulawa ta yanayin haihuwa wani rubutu daga china na cewa a raba tsakanin uwa mai dauke da wannan cuta da kuma abun da ta haifa tsawon kwana 14.
In the US there is also the recommendation that newborns and mothers should be temporarily separated until transmission-based precautions are discontinued, and that where this is not possible the newborn should be kept 2 metres away from the mother.
A Amurka akwai kuma shawarar cewa ya kamata a raba jarirai da uwaye na wani dan lokaci har sai an daina yin amfani da hanyoyin kariya, kuma a inda ba zai yiwu ba a kiyaye jariri mai nisan mil 2 daga mahaifiyar.
b'COVID-19 surveillance involves monitoring the spread of the coronavirus disease in order to establish the patterns of disease progression.
Sanya ido kan b’COVID-19 ya ƙunshi saka idanu kan yaduwar cutar coronavirus domin kafa tsarin ci gaban cutar.
The World Health Organization (WHO) recommends active surveillance, with focus of case finding, testing and contact tracing in all transmission scenarios.
Hukumar Lafiya Ta Duniya (WHO) ta shawaci sa ido sosai, da mai da hankali a neman masun kamuwa da cutan, gwadawa da gano wadanda suka hulda da marasa lafiya a dukan yanayin yaduwa.
COVID-19 surveillance is expected to monitor epidemiological trends, rapidly detect new cases, and based on this information, provide epidemiological information to conduct risk assessment and guide disease preparedness.
kula da covid-19 na zato zai duba hauhawar epidimology tare da gano sababin kamuwa, kuma dangane dsa wannan bayanana zai bada sirrin hadarin gawje gwajen epidemology dama bada shrin kariya na cutar.
Syndromic surveillance is done based on the symptoms of an individual that corresponds to COVID-19.
Ana gudanar da aikin kulawa na Syndromic dangane da alamun mutum wanda ya dace da COVID-19.
As of March 2020, the WHO recommends the following case definitions:
A watan maris 2020, WHO ta bukaci amfanar wannan lamuran:
Probable case : "A suspect case for whom testing for the COVID-19 virus is inconclusive" OR "a suspect case for whom testing could not be performed for any reason".
Yiwuwa harka: "Harka wanda ake zargi ga wanda ke yin gwajin kwayar COVID-19 ba a haɗa shi ba" KO "harka wanda ake zargi wanda ba za a iya yin gwajin ba saboda kowane dalili".
Confirmed case: "A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms".
tabbacin mai dauke da ita mutum yana dauke da ita cutar covid-19 ko da kuwa ba shi da alamun da a gwajin lafiya ko bibbinin ya.
Direct physical contact with a probable or confirmed case;
Haduwa ta jiki kai tsaye tare da mai yiwuwa ko tabbataccen cutar;
Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment;
Kulawa ta kai tsaye ga mara lafiya tare da mai yiwuwa ko aka tabbatar da cutar COVID-19 ba tare da amfani da ingantattun kayan kariya na sirri ba;
Other situations as indicated by local risk assessments".WHO recommends reporting of probable and confirmed cases of COVID-19 infection within 48 hours of identification.
Sauran damu’oi yadda aka kimmanta hadarin cikin gida "WHO ta ba da shawarar bada rahoton yiwuwar da an tabbatacen kamuwa da cutar COVID-19 a cikin sa'o'i 48 na ganowa.
The countries should report on a case-by-case basis as far as possible, but in case of limitation in resources, aggregate weekly reporting is also possible.
kasa su rinka rahoton masjinyata amman vin ba hali a bada ra hoton sati.
Some organizations have created crowdsourced apps for syndromic surveillance, where people can report their symptoms to help researchers map areas with concentration of COVID-19 symptoms.
wasu kungiyoyin sun kin kira manhajar tattara jama’am don bibbyar syndromic inda mutane ka iya kawo karar abun da suke ji din bawa masu bincike damar gane inda mafi yawan masu cutar suke a taswira na covid-19.
Virological surveillance is done by using molecular tests for COVID-19.
Dubiyar virological ana yin shine ta hanyar amfani da gwajin molecular na Covid-19.
WHO has published resources for laboratories on how to perform testing for COVID-19.
WHO ta wallafa albarkatu don gidan gwaje-gwaje kan yadda ake yin gwaji don COVID-19.
In the European Union, laboratory confirmed cases of COVID-19 are reported within 24 hours of identification.
Cikin dakin gwajin Kungiyar Turai sun ba da tabacin gwajin wanda suka kamu da cutar COVID-19 cikin sa’oi 24 bayan ganowa.
At least 24 countries have established digital surveillance of their citizens.
A Kalla Kasashe 24 sun samar da dibiyar zamani ga ‘iyan Kasar su.
The digital surveillance technologies include apps, location data and electronic tags.
Kayan Saka ido kan marasa ta hanyar na’uran dijital sun hada da manahaja, bayanan wuri da alamun lantarki.
The Center For Disease Control and Prevention in USA tracks the travel information of individuals using airline passenger data.
Cibiyar Kariya da Lurawar Cuta wato Center For Disease Control and Prevention a USA ta bibbiyar bayanan fasinjoji jirgi.
In Hong Kong, authorities are requiring a bracelet and an app for all travellers.
A Hong Kong, hukumomi suna buƙatar munduwa da app ga duk matafiya.
A GPS app is used to track the locations of individuals in South Korea to ensure against quarantine breach, sending alerts to the user and to authorities if people leave designated areas.
Ana amfani da app ta GPS don bin diddigin wuraren mutane a Koriya ta Kudu don tabbatar da keta dokar hana fita, tana aika da faɗakarwa ga mai amfani da kuma hukumomi idan mutane suka bar wuraren da aka tsara.
In Singapore, individuals have to report their locations with photographic proof.
A cikin Singapore, mutane dole ne su ba da rahoton wuraren zama tare da tabbacin hoto
Thailand is using an app and SIM cards for all travelers to enforce their quarantine.
thailand na amfani da jadawali da katin SIM don bibbyay matafiya akan kene kan su.
Human rights organizations have criticized some of these measures, asking the governments not to use the pandemic as a cover to introduce invasive digital surveillance.
Kungiyoyin kare hakkin dan adam sun zargi wasu matakai, suna tambayar gwamnatoci da kada su yi amfani da annoban a matsayin wata rufa-rufa wajen gabatarwa da Sa ido kan marasa lafiya ta hanyar na’uran dijital.
b'A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19).
allurar rigakafin b'A COVID-19 maganin rigakafin cutar coronavirus 2019 (COVID-19).
Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
Kodayake babu maganin alurar riga kafi da ya kammala gwajin asibiti, akwai ƙoƙarin da yawa a cikin ci gaba don haɓaka irin wannan maganin.
In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS-CoV-2, the causative virus, to become available in less than 18 months.
A ƙarshen Fabrairu 2020, Hukumar Lafiya ta Duniya (WHO) ta ce ba ta tsammanin samun allurar rigakafin ƙwayar cutar SARS-CoV-2, ta zama ƙasa da watanni 18.
Five vaccine candidates were in Phase I safety studies in April.
‘Yan maganin rigakafi su biyar na cikin Mataki I na karatun lafiya cikin Afrilu.
COVID-19 was identified in December 2019.
An gano covid-19 a december 2019.
A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.
A wa ni barkewar a duniya a 2020 yasa karin haniun jari a BINCIKEN NEMAN MAGANI.
Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.
Kungiya da yawa na amfani da kwayar halita genomes ta wajen haɓakawar maganin rigakafin SARS-CoV-2.
Stated in April, imperatives of the CEPI initiative for vaccine development are speed, manufacturing capacity, deployment at scale, and global access.
An fara shi a watan Afrilu, muhimancin himmar CEPI don haɓaka maganin rigakafi da wuri, yawan sarrafawa, turawa da yawa, da samun sa a duk duniya.
In April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID-19.
A watan Afrilu, masanan kimiyya na CEPI sun ba da rahoton cewa hanyoyin fasahar fasaha daban-daban 10 suna ƙarƙashin bincike da haɓakawa a farkon 2020 don ƙirƙirar ingantaccen allurar rigakafin COVID-19.
Major platform targets advanced into Phase I safety studies include:
zauruka dayawa sun danawa sihag cigaban shashi na I akan karatun kariya kamar;
nucleic acid (DNA and RNA) (Phase I developer and vaccine candidate: Moderna, mRNA-1273)
nucleic Acid (DNA Da RNA) (Mataki I mai haɓakawa da masun maganin rigakafii: Moderna, mRNA-1273)
viral vector (Phase I developer and vaccine candidate: CanSino Biologics, adenovirus type 5 vector)
viral vector (Tsarin I na haɓakawa kuma ɗan takarar alurar rigakafi: CanSino Biologics, adenovirus type 5 vector)
As reported by CEPI scientists in April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the Milken Institute), and 37 others announced, but with little public information available (presumed to be in planning or being designed).
Wani rahoton cepi na masu fasaha a watan afrilu, magunguna 115 aka fara kerowa da 78 tabbatatu masu cigaba 79 a cewar makarantar miken 37 son sanar amman babu bayani a cikin alumma ana zaton suna tsari ko shiryawa a dakunan gwaji da dama.
A Phase I-II trial conducts preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, and at multiple sites, while determining more precise, effective doses.
A shashe na I-II na gwajin kiyayewar farko da gwajin garkuwa, ana hade sune ba zabi kuma ba riko da wajen kuma a waje dayawa, wanda ke bada sahihanci dama ingantacen kima.
Phase III trials typically involve more participants, including a control group, and test effectiveness of the vaccine to prevent the disease, while monitoring for adverse effects at the optimal dose.
Gwajin matakai na III yawanci ya ƙunshi ƙarin mahalarta, gami da rukuni na sarrafawa, da gwajin tasiri na cutar rigakafin don hana cutar, yayin sa ido don tasirin mummunar sakamako mafi kyau.
Of 79 vaccine candidates in active development (confirmed as of early April 2020), 74 were not yet in human evaluation (still in "preclinical" research).
Daga cikin 'yan gwajin rigakafin 79 a cikin ci gaba (wanda aka tabbatar da shi tun farkon Afrilu 2020), 74 ba su kasance cikin kimantawar ɗan Adam ba (har yanzu suna cikin "preclinical” bincike).
Around 24 January 2020 in Australia, the University of Queensland announced that it is investigating the potential of a molecular clamp vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.
Kusan ran 24 ga watar Janairu shekarar 2020 a Ostiraliya, Jami'ar Queensland ta ba da sanarwar cewa tana binciken yiwuwar rigakafin ƙwayar cuta wanda zai iya canza kwayar furotin don ta tada tsarin garkuwa.
Around 24 January 2020 in Canada, the International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan announced the commencement of work on a vaccine, aiming to start human testing in 2021.
A kusan 24 Janairu 2020 a kasar Kanada, Cibiyar Kula da Alurar rigakafi ta Duniya (VIDO-InterVac) a Jami'ar Saskatchewan ta ba da sanarwar fara aiki a kan allurar rigakafin, da nufin fara gwajin ɗan adam a cikin 2021.
Vaccine development projects were announced at the Chinese Center for Disease Control and Prevention on 26 January 2020, and the University of Hong Kong on 28 January.
An sanar da Ayyukan haɓakawar Rigakafi A Hukumar Kula Da Karewar Daga Cuta A 26 ga watar Junairu 2020 A China, Da Jami'ar Honk Kong a ranar 28 ga watan Janairu.
Around 29 January 2020, Janssen Pharmaceutical Companies, led by Hanneke Schuitemaker, announced that it had begun work on developing a vaccine.
A wuraren 29 ga watan junairu 2020 kamfanoni magungunna na jassen wanda henneke schuitemaker ke jagoranta, su sanar da fara kirkikra maganin.
Janssen is co-developing an oral vaccine with its biotechnology partner, Vaxart.
janssen na kirkiro magani na rowa tare da abokin huldar shir wadan ya kware a dakin gwaji vaxart.
On 18 March 2020, Emergent BioSolutions announced a manufacturing partnership with Vaxart to develop the vaccine.
A ranar 18 ga watan Maris 2020, Emergent BioSolutions sun ba da sanarwar hadin gwiwan sarrafawa tare da Vaxart don haɓakar maganin rigakafi.
On 8 February 2020, the laboratory OncoGen in Romania published a paper on the design of a vaccine with similar technology to the one used for cancer neoantigen vaccination therapy.
A ranar 8 ga Fabrairu 2020, dakin gwaje-gwaje na OncoGen a Romania sun buga takarda kan ƙirar rigakafin tare da fasaha mai kama da wannan don maganin rigakafin cutar kansa.
On 25 March the head of the research institute announced that they had finalized the synthesis of the vaccine and were beginning the tests.
A ranar 25 Ga Watan Maris Shugaban Makarantar Bincike ya sanar cewa sun gama hadawar Rigakafin kuma and fara gwajin ta.
On 27 February 2020, a Generex subsidiary company, NuGenerex Immuno-Oncology, announced they were beginning a vaccine project to create an Ii-Key peptide vaccine against COVID-19.
A ranar 27 ga Fabrairu 2020, wani kamfanin tallafi na Generex, NuGenerex Immuno-Oncology, ya ba da sanarwar cewa sun fara aikin rigakafin cutar don kirkirar wani allurar rigakafin Ii-Key a kan COVID-19.
They wanted to produce a vaccine candidate that could be tested in humans "within 90 days."
Suna So Su Samar Da Rigakafin Da Za A Iya Gwada Shi A Kan Mutum “A tsakanin Kwanaki 90.”
On 5 March 2020, Washington University in St. Louis announced its projects to develop a vaccine.
A ranar 5 Maris 2020, Jami'ar Washington da ke St. Louis ta ba da sanarwar ayyukanta don bunkasa allurar rigakafi.
On 5 March 2020, the United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research in Silver Spring, both in western Maryland, announced they were working on a vaccine.
A rana 5 ga watan Maris 2020, aurka makarantar sojin ta su n vyi vbincvike a fort derick da walter reed da makarantar bincike na silver spring duk a western mary lant sun sanar da aikin ne man nagani.
Around 10 March 2020, Emergent Biosolutions announced that it had teamed with Novavax Inc.
A kusan 10 Maris 2020, Emergent Biosolutions ya ba da sanarwar cewa ta yi ma'amala tare da Novavax Inc.
in the development and manufacture of a vaccine.
a hadin da ma kir-kirar magani.
The partners further announced plans for preclinical testing and a Phase I clinical trial by July 2020.
Abokan haɗin gwiwar sun kara ba da sanarwar shirye-shiryen gwajin fari da Mataki I na gwajin asibiti a watan Yuli 2020.
On 12 March 2020, India's Health Ministry announced they are working with 11 isolates, and that even on a fast track it would take at least around one-and-a-half to two years to develop a vaccine.
A ranar 12 Maris 2020, Ma'aikatar Lafiya ta Indiya ta sanar da cewa suna aiki tare da kebe guda 11, kuma koda akan saurin sauri zai ɗauki akalla shekara ɗaya da rabi zuwa shekara biyu don samar da maganin.
On 12 March 2020, Medicago, a biotechnology company in Quebec City, Quebec, reported development of a coronavirus-like particle under partial funding from the Canadian Institutes for Health Research.
A ranar 12 ga watan Maris 2020, Medicago, kamfani a fannin ilimin halittu a Birnin Quebec, Quebec, ya ba da rahoton ci gaban coronavirus-kamar ɓarke ƙarƙashin ɓangare na kudade daga Makarantun Kanada don Binciken Kiwon Lafiya.
The vaccine candidate is in laboratory research, with human testing planned for July or August 2020.
Maganin riga kafin da ake gwaji Na Cikin Dakin Bincike, Da tsarin gwajin a watan Yuly Ko AuGusta 2020.
Earlier that week, The Guardian reported that the US President Donald Trump had offered CureVac "'large sums of money' for exclusive access to a Covid-19 vaccine", against which the German government protested.
A farkon makon nan, Jaridar The Guardian ta bayar da rahoton cewa Shugaban Amurka Donald Trump ya yi wa CureVac '' kudade masu yawa 'don damar samun damar yin amfani da allurar rigakafin cutar ta' 'Covid-19', wanda gwamnatin Jamus ta nuna rashin amincewarta.
On 17 March 2020, American pharmaceutical company Pfizer announced a partnership with German company BioNTech to jointly develop a mRNA-based vaccine.
Ranar 17 ga watan Maris 2020, Kamfanin maganin Amurka Pfizer ta sanar da hadin gwiwa tare da kamfanin BioNTech na Jamus don haɓaka rigakafi irin ta mRNA.
mRNA-based vaccine candidate BNT162, currently in pre-clinical testing with clinical trials expected to begin in April 2020.
magani irin na mRNA-based dan bNT162, wanda a yanzu ke cikin gwajin lafiya ana tsamanin shi a april 2020.
In Italy on 17 March 2020, Takis Biotech, an Italian biotech company announced they will have pre-clinical testing results in April 2020 and their final vaccine candidate could begin human testing by fall.
A Italiya a ranar 17 Maris 2020, Takis Biotech, wani kamfani na ilimin kimiyyar kere-kere na Italiya ya sanar da cewa za su sami sakamakon gwajin-asibiti a watan Afrilu 2020 kuma dan takarar na karshe na rigakafin cutar zai iya fara gwajin dan adam da faduwa.
In France on 19 March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced a US$4.9 million investment in a COVID-19 vaccine research consortium involving the Institut Pasteur, Themis Bioscience (Vienna, Austria), and the University of Pittsburgh, bringing CEPI's total investment in COVID-19 vaccine development to US$29 million.
A Faransa a ranar 19 Maris 2020, Kungiyar Hadin Gwiwa game da Cike da cuta (CEPI) ta sanar da saka hannun jari na dala miliyan $ 4.9 a cikin wata cibiyar bincike ta COVID-19 wacce ta shafi Institut Pasteur, Themis Bioscience (Vienna, Austria), da Jami'ar Pittsburgh, suna kawowa, Jami'ar Pittsburgh, suna kawowa Jami'ar Pittsburgh, suna kawo Kudaden hannun jarin CEPI a cikin ci gaban allurar rigakafin COVID-19 zuwa dala miliyan 29.
CEPI's other investment partners for COVID-19 vaccine development are Moderna, Curevac, Inovio, Novavax, the University of Hong Kong, the University of Oxford, and the University of Queensland.
Sauran abokan hadin gwiwar CEPI don ci gaban allurar rigakafin COVID-19 sune Moderna, Curevac, Inovio, Novavax, Jami'ar Hong Kong, Jami'ar Oxford, da Jami'ar Queensland.
On 20 March 2020, Russian health officials announced that scientists have begun animal testing of six different vaccine candidates.
A ranar 20 ga Maris 2020, jami’an kiwon lafiya na kasar Rasha sun ba da sanarwar cewa masana kimiyya sun fara gwajin dabbobi daban-daban ‘yan takarar rigakafi shida.
Imperial College London researchers announced on 20 March 2020 that they are developing a self-amplifying RNA vaccine for COVID-19.
Masu binciken Kwalejin Kwaleji ta Landan sun sanar a ranar 20 ga Maris 2020 cewa suna haɓaka maganin RNA na karɓar kansa don COVID-19.
The vaccine candidate was developed within 14 days of receiving the sequence from China.
Aka haɓaka maganin rigakafin cikin kwanaki 14 ya inda aka samo jerin gwajin daga China.
In late March, the Canadian government announced C$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian companies and universities, such as the Medicago and University of Saskatchewan initiatives.
A ƙarshen watan Maris, gwamnatin Kanada ta ba da sanarwan miliyan C$275 a cikin kudade don ayyukan bincike na 96 a kan magungunan ƙetare game da COVID-19, hade da takara da yawa na allurar rigakafi a kamfanoni da jami'o'in Kanada, kamar ayyukan Medicago da Jami'ar Saskatchewan.
Around the same time, the Canadian government announced C$192 million specifically for developing a COVID-19 vaccine, with plans to establish a national "vaccine bank" of several new vaccines that could be used if another coronavirus outbreak occurs.
A kusan lokaci guda, Gwamnatin Kanada ta ba da miliyan C$192 musamman don inganta allurar rigakafin COVID-19, tare da shirye-shiryen kafa "bankin maganin rigakafin" na ƙasa na wasu sabbin alluran rigakafin da za a iya amfani da su idan wani barkewar cutar coronavirus ya faru.
On 2 April 2020, researchers at the University of Pittsburgh School of Medicine reported on testing of PittCoVacc, a possible COVID-19 vaccine in mice, stating that "MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses [in the mice] that were evident beginning 2 weeks after immunization."
A ranar 2 ga Afrilu 2020, masu bincike a Jami'ar Pittsburgh makarantar ilimin magani sun ba da rahoto game da gwajin PittCoVacc, yiwuwar maganin rigakafin COVID-19 a cikin beraye, yana mai cewa "MNA ta ba da ƙarancin SARS-CoV-2 S1 allurar rigakafin ta nuna yiwuwar antigen-specific amsawar garkuwar jiki [a cikin bera] wadanda suka fara bayyana makonni 2 bayan alurar rigakafi."
In Canada on 16 April 2020, the University of Waterloo School of Pharmacy announced design of a DNA-based vaccine candidate as a possible nasal spray.
a canada a ranar 16 ga watan afrilu 2020, makarantar magunguna karkashin jamiar waterloo sun sanar da feshin hanci a matsayin maganin su na kwayar halittar DNA.
Using bacteriophages, the DNA will be designed to replicate inside human bacteria to produce harmless virus-like particles, which may stimulate the immune system to produce antibodies against the SARS-CoV-2 virus.
Amfani da kwayoyin cuta, ana tsara kwayar halitta ta DNA don yin kwayar cutar cikin jikin dan adam don samar da kwayoyin cuta marasa cutarwa, wadanda zasu iya tayar da tsarin garkuwar jiki don samar da kwayoyin kariya daga kwayar ta SARS-CoV-2.
In March 2020, the US government, industry, and three universities pooled resources to access supercomputers from IBM, combined with cloud computing resources from Hewlett Packard Enterprise, Amazon, Microsoft, and Google.
A watan Maris 2020, gwamnatin amurka , masana’antu da ma wasu jami’oi guda uku sun hada karfi don samar da nau’rori dag kamfanin IBM da ma ayukan bayan sirri na yanar gizo daga kamfanin Hewlett Packard, amazon, microsoft da ma Google.
Some vaccines have heterologous effects, also called non-specific effects.
Wasu magungunan rigakafin suna da tasirin cutar heterologous, wanda kuma ake kira tasirin da ba na takamaiman sakamako ba.
That means they can have benefits beyond the disease they prevent.
Hakan yana nufin suna iya samun fa'idodi fiye da cuta wanda aka kare.
A further randomized trial in Australia is seeking to enrol 4,170 healthcare workers.
Wani ci gaban gwajin da aka yi barkatai a Australia Yana Neman shigarwan ma’aikacin kiwon lafiya guda 4,170
It is possible vaccines in development will not be safe or effective.
Yana yiwuwa rigakafin a cikin ci gaba ba zai zama da aminci ko tasiri ba.
Early research to assess vaccine efficacy using COVID-19-specific animal models, such as ACE2-transgenic mice, other laboratory animals, and non-human primates, indicate a need for biosafety-level 3 containment measures for handling live viruses, and international coordination to ensure standardized safety procedures.
Binciken farko domin samun ingancin rigakafin ta yin amfani da CoVID-19 ƙayyadaddu tsarin dabbobi, kamar ACE2-transgenic bera, da ma wasu dabobin dakin Gwaji da wadanda asalin su ba Mutum ba ne, sun nuna bukatar aunawar tsarewan mataki uku na lafiyar halita wato biosafety-level 3 na rikewar kwayar cuta masu rai, da daidaituwan duniya domin tabbatar da tsarin lafiya.
Vaccines against SARS and MERS have been tested in non-human animal models.
An yi maganin rigakafin cutar SARS da MERS a cikin samfurin dabba na mutane.
As of 2020, there is no cure or protective vaccine for SARS that has been shown to be both safe and effective in humans.
Har zuwa 2020, babu wani maganin warkarwa ko rigakafin kariya daga SARS wanda aka nuna yana da kyau da tasiri a cikin mutane.
According to research papers published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around the world.There is also no proven vaccine against MERS.
Dangane da takardun bincike da aka buga a 2005 da 2006, ganowa da haɓaka allurar rigakafi da magunguna don magance SARS ya kasance fifiko ga gwamnatoci da hukumomin kiwon lafiyar jama’a duniya. Hakanan babu wani ingantaccen maganin alurar rigakafi kan MERS.
When MERS became prevalent, it was believed that existing SARS research may provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.
Lokacin da MERS ya zama ruwan dare, an yi imanin cewa bincike na SARS wanda akwai na iya samar da samfuri mai amfani don ci gaba da allurar rigakafi da warkewa game da kamuwa da cutar MERS-CoV.
As of March 2020, there was one (DNA based) MERS vaccine which completed phase I clinical trials in humans, and three others in progress, all of which are viral-vectored vaccines, two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac), and one MVA-vectored (MVA-MERS-S).
Tun daga Maris 2020, akwai allurar rigakafi (bisa ga DNA) MERS wanda ya ƙare Matak I gwaji na asibiti a cikin mutane, da kuma wasu uku da ke ci gaba, dukkan waɗannan rigakafi ne na masu tafiya da kwayoyin cuta, adenoviral-vectored guda biyu (ChAdOx1-MERS, BVRS-GamVac ), kuma MVA-vectored (MVA-MERS-S).
Social media posts have promoted a conspiracy theory claiming the virus behind COVID-19 was known and that a vaccine was already available.
Tura rubutu ta hanyar sadarwar sun inganta wata ka'ida tunani mai zurfi masu cewa an san kwayar cutar da ke haifar da COVID-19 kuma an riga an sami allurar rigakafi.
The patents cited by various social media posts reference existing patents for genetic sequences and vaccines for other strains of coronavirus such as the SARS coronavirus.
Abubuwan da aka ambata waɗanda aka buga ta hanyar kafofin watsa labarun daban-daban na kafofin watsa labarun suna ambatar bayanan da suka kasance game da jerin kwayoyin da kuma alurar rigakafin wasu ƙwayar cuta ta coronavirus kamar SARS coronavirus.
b'Coronaviruses are a group of related viruses that cause diseases in mammals and birds.
b’Coronaviruses wasu rukuni ne wanda suke da alaƙa da juna suna bada cututtuka ga dabbobi da sunsaye.
In humans, coronaviruses cause respiratory tract infections that can range from mild to lethal.
A mutane, cutar corona na saka matsalar numfashi da ga kadan har izuwa tsanani.
Mild illnesses include some cases of the common cold (which has other possible causes, predominantly rhinoviruses), while more lethal varieties can cause SARS, MERS, and COVID-19.
Tsanani ciwo ciki harda alamun sanyi wanda ke da abubuwa da dama masu janyo shi kamar cutR RHINO KO MA mafi tsanani kaman su SARS MERS DA COVID-19.
Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea.
Kwayar cutar a cikin wasu nau'ikan sun bambanta: a cikin kaji, suna haifar da cututtukan hanji na sama, yayin da a cikin shanu da aladu suna haifar da gudawa.
There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.
babu magani ko rigakafi na mutane ma curar.